In situ **cyclodehydration of iminodiacetic acid into 2,5-diketopiperazine-1,4-diacetate in lanthanide-based coordination polymers†**

Xiang-Jian Kong,*^a* **Gui-Lin Zhuang,***^a* **Yan-Ping Ren,****^b* **La-Sheng Long,****^a* **Rong-Bin Huang***^a* **and Lan-Sun Zheng***^a*

Received 5th November 2008, Accepted 16th January 2009 First published as an Advance Article on the web 26th January 2009 **DOI: 10.1039/b819792j**

The reaction of iminodiacetic acid with $Ln₂O₃$ (Ln = Dy, **Ho, Er, Yb) under hydrothermal conditions generate a series of 3D lanthanide-based coordination polymers, in which, the iminodiacetic acid (IDA) was transformed into a 2,5 diketopiperazine-1,4-diacetate.**

As a new bridge in both coordination chemistry and organic chemistry, hydrothermal *in situ* ligand synthesis is becoming an important subject in the field of organic synthesis and crystal engineering.**1–3** Although difficult to design, hydrothermal *in situ* ligand synthesis not only provides the organic compound, which is difficult to obtain through routine synthetic methods,**3a,3c** but also new types of coordination polymers with potential applications.**2c** Until now, more than 10 types of hydro(solvo)thermal *in situ* ligand syntheses have been found, such as hydroxylation,**⁴** alkylation,**⁵** carbon–carbon bond formation,**⁶** hydrolysis,**⁷** tetrazole and triazole formation,**⁸** acylation**⁹** and others.**¹⁰**

2,5-Diketopiperazine-1,4-diacetic, as one of the smallest cyclic dipeptide derivatives, is considered to be a privileged structure for drug development**¹¹** and for peptide chemistry studies.**12–13** Its structural characteristic also makes it become a potential molecular building block for the assembly of coordination polymers. So far, the dimerization of iminodiacetic acid or its esters remains to be an important method to the preparation of the compound, despite that the yield is rather low.**¹⁴** In 2003, Silva and co-workers**¹⁵** found that the cyclization of iminodiacetic acid dimethyl ester in the presence of NiCl_2 could generate 2,5-diketopiperazine-1,4diacetic, but the yield was unclear. Here, we report our observation of *in situ* cyclization of iminodiacetic acid in lanthanide-based coordination polymers, namely, $[Ln_2(\alpha x)_2L(H_2O)_2]$ _n (Ln = Dy (1), Ho (2) , Er (3) , Yb (4) ; L = 2,5-diketopiperazine-1,4-diacetate, ox = oxalate). An investigation on the factors influencing the formation of the organic ligand shows that oxalic acid plays a key role in the formation of the 2,5-diketopiperazine-1,4-diacetate ligand.

The block crystals of **1**–**4** were obtained by hydrothermal reactions of $Ln₂O₃$ (Ln = Dy, Ho, Er, Yb), iminodiacetic acid, oxalic acid, HNO₃ and water in a molar ratio of $1 : 4 : 2 : 6 : 550$ at 180 *◦*C for 100 h.‡ Interestingly, this reaction results in *in situ* transformation of 2,5-diketopiperazine-1,4-diacetic acid through intermolecular dehydration coupling of iminodiacetic acid (Scheme 1). Single-crystal analysis reveals that complex **1** consists of two Dy(III) cations, one 2,5-diketopiperazine-1,4-diacetate, two αx^2 ligands and two water molecules. Each Dy(III) center is located in a square anti-prism geometry and is coordinated by two monodentate carboxylate groups from two 2,5-diketopiperazine-1,4-diacetate ligands, one carboxyl group of 2,5-diketopiperazine-1,4-diacetate ligand, two ox^2 ligands in chelate mode and one water molecule as shown in Fig. 1. The bond lengths of Dy–O are in the range from 2.266(2)–2.423(3) Å, very close to those in the complex $[Dy_3Cu_6L_6(OH)_6(H_2O)_{10}]\cdot Cl_2\cdot ClO_4\cdot 3.5H_2O^{16}$

Scheme 1 Schematic view of hydrothermal *in situ* generation of 2,5-diketopiperazine-1,4-diacetic acid.

Fig. 1 ORTEP plot showing the coordination environment of the Dy(III) center in **1**. Symmetry transformations: $(A) - x + 1$, $-y + 2$, $-z$; $(B) - x + 1$, $-y + 1$, $-z + 1$; (D) $-x + 1$, $-y + 2$, $-z + 1$.

The structure of **1** can be described as follows: (1) two adjacent $Dy(H_2O)^{3+}$ cations linked by αx^2 to form a 1D chain of $[Dy(H_2O)(ox)]_n^*$ as illustrated in Fig. 2; (2) 2,5-diketopiperazine-1,4-diacetate acts as a 4-connected node to link the adjacent 1D chains through each carboxylate and carboxyl group coordinated with one $Dy(III)$ cation from the adjacent 1D chains to generate a 2D layered structure of $[Dy_2(ox)_2L(H_2O)_2]$ _n as shown in

a State Key Laboratory of Physical Chemistry of Solid Surfaces, Department of Chemistry and College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China. E-mail: lslong@xmu.edu.cn; Fax: +86 592 218 3047

b The Key Laboratory of Analytical Sciences of the Ministry of Education, Department of Chemistry and College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China. E-mail: ypren@xmu.edu.cn † Electronic supplementary information (ESI) available: X-Ray crystallographic files in cif format for the four complexes, the electrospray mass spectrum for the reactions of IDA + $\alpha x + Ln_2O_3$ (Ln = Dy), IDA + $HNO₃ + Ln₂O₃$ (Ln = Dy), IDA +Ln₂O₃ (Ln = Dy) and IDA + ox + $HNO₃ + Ln₂O₃$ (Ln = Pr, Eu) (Fig. S1–6), ¹H NMR spectra (Fig. S2) and magnetic properties (Fig. S3) for the four complexes. CCDC reference numbers 708190–708193. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/b819792j

Fig. 2 ORTEP plot showing the 1D chain of $[Dy(H_2O)(ox)]_n^{n+1}$ in 1.

Fig. 3 and (3) two adjacent 2D layers further extend into a 3D structure through the uncoordinated carboxylate group of 2,5 dioxopiperazine-1,4-diacetate from one layer to the Dy(III) cation from adjacent layers as shown in Fig. 4. As a result, each ligand in **1** is coordinated to six Dy(III) ions with four from the same layer and two from the adjacent layers. It was noted that complex **1** is the first 2,5-diketopiperazine-1,4-diacetate metal complex on the basis of a survey of the Cambridge Crystallographic Database.**¹⁷**

Fig. 3 Stick plot showing the 2D layer in **1**.

Fig. 4 Stick plot showing the 3D structure of **1**.

The crystal structures of **2**, **3** and **4** are isomorphous with the framework of **1**.§ The bond lengths of Ln–O are 2.249(2)– 2.409(2), 2.232(2)–2.392(2) and 2.224(2)–2.390(3) A˚ for **2**, **3** and **4**, respectively, comparable to those in **1**.

In order to understand the key factor to affect the formation of the organic ligand, we used IDA + ox + Dy_2O_3 , IDA + HNO₃ + Dy_2O_3 , IDA + Dy_2O_3 and IDA + ox + HNO₃ + Ln₂O₃ (Ln = Pr, Eu) to prepare the organic ligand under similar conditions to that of **1**. In these reactions, we could obtain crystals of **1** only in the cases of $IDA + ox + Ln₂O₃$ (Ln = Dy) (the yield for the reaction of IDA + $ox + Ln₂O₃$ is very close to that of IDA + ox + HNO₃ + Ln₂O₃), and obtained 3D complex $Ln_2(ox)_3(H_2O)_6^{18}$ for the reaction of IDA + $ox + HNO₃ + Ln₂O₃$ (Ln = Pr, Eu), while in the remaining case, we either obtained a clear solution (for the reaction of $IDA + HNO₃ +$ $Ln₂O₃$) or a suspending solution (for the reaction of IDA +Ln₂O₃). However, the electrospray mass spectra show that the residual

solutions of all the reactions contains the 2,5-diketopiperazine-1,4-diacetate ligand (ESI, Fig. S1–6†), and the amount of the 2,5 diketopiperazine-1,4-diacetate ligand in the residual solution of the reaction of IDA + ox + Ln₂O₃ and IDA + ox + HNO₃ + Ln₂O₃ $(Ln = Pr, Eu)$ is significantly higher than that in the reactions of $IDA + ox + HNO₃ + Ln₂O₃, IDA + HNO₃ + Ln₂O₃ and IDA +$ $Ln₂O₃$. These results indicate that it is oxalic acid, instead of the lanthanide ion and $HNO₃$ that plays a key role in the formation of the 2,5-diketopiperazine-1,4-diacetate ligand. Hence, IDA and oxalic acid was used to synthesize the 2,5-diketopiperazine-1,4 diacetate ligand. When the mixture of iminodiacetic acid (0.27 g, 2.0 mmol) and oxalic acid (0.12 g, 2.0 mmol) was sealed in a 25 mL Teflon-lined stainless steel container and heated to 180 *◦*C for 100 h, then cooled to 100 *◦*C at a rate of 3 *◦*C h-¹ and held for 16 h, followed by further cooling to 100 *◦*C at a rate of 5 *◦*C h-¹ , colourless crystals of 2,5-diketopiperazine-1,4-diacetic acid was obtained in a yield of more than 85%. The organic ligand was further confirmed by ${}^{1}H$ NMR spectra (ESI, Fig. S2†) and singlecrystal structure analysis. Measurement of the temperature-dependent magnetic proper-Versions of all the neurions contains the 2.5-dikesperies of all the secondary of the control of \mathbb{R}_2 . The secondary of the control of \mathbb{R}_2 . The secondary \mathbb{R}_2 and \mathbb{R}_2 (\mathbb{R}_2 CO) and \mathbb{R}_2 ($\$

ties of **1**, **2**, **3** and **4** was carried out at an applied magnetic field of 1000 Oe over the temperature range 2–300 K. The temperature dependence of the magnetic susceptibilities in the form of μ_{eff} *vs. T* for **1**, **2**, **3** and **4** are shown in ESI Fig. S3.† The μ_{eff} value per molecule of 1 is $15.15\mu_B$ at room temperature, close to the expected value of $15.05\mu_B$ for two free non-interacting Dy(III) ions. Upon lowering the temperature, μ_{eff} decreases gradually to $15.01\mu_{\text{B}}$ at 50 K, and then drops rapidly below 50 K to $13.6\mu_B$ at 2 K. The dramatic decrease of μ_{eff} at low temperature is mainly attributed to the weak antiferromagnetic coupling between the Dy(III) ions, and partially to the splitting of the ligand field of the Ln(III) ion.**19,20** Similar to 1, the varieties of the temperature dependence of $\mu_{\rm eff}$ can also be found in complexes 2 and 3. For 4, the μ_{eff} value at 300 K is $6.16\mu_{\rm B}$, which is close to the expected value for two isolated $Yb(III)$ ions (calculated 6.41 μ_B). However, there is a continuous decrease in μ_{eff} and it reaches 4.35 μ_{B} at 2K with the decrease of the temperature, which mainly indicates the feature of single Yb(III).**19a**

In summary, we have reported the syntheses and crystal structures of four lanthanide-based 3D coordination polymers through hydrothermal reaction of $Ln₂O₃$ (Ln = Dy, Ho, Er, Yb), iminodiacetic acid, oxalic acid and HNO₃. In these compounds, the iminodiacetic acid was transformed into a 2,5-diketopiperazine-1,4-diacetate. Further investigation shows that oxalic acid plays a key role in the formation of 2,5-diketopiperazine-1,4-diacetic acid. The extension of such a synthetic approach into other kind of cyclic dipeptides is under the way.

Acknowledgements

We thank the NNSFC (grant no. 20825103 and 20721001), the 973 Project from MSTC (grant 2007CB815304) and the Natural Science Foundation of Fujian Province of China (grant no. 2008J0010) for financial support.

Notes and references

‡ Complex **1** was synthesized as follows: iminodiacetic acid (0.27 g, 2.0 mmol), oxalic acid (0.12 g, 2.0 mmol), Dy_2O_3 (0.187 g, 0.5 mmol) and HNO₃ (0.25 mL, 3 mmol,) were mixed in 10.0 ml water with stirring at room temperature. The mixture was transferred and sealed in a 25 mL

Teflon-lined stainless steel container. The container was heated to 180 *◦*C and held at that temperature for 100 hour, then cooled to 100 *◦*C at a rate of 3 *◦*C h-¹ and held for 16 h, followed by further cooling to 100 *◦*C at a rate of 5 *◦*C h-¹ . Colourless crystals of **1** were collected in 170 mg (45% yield based on Dy_2O_3). Compounds 2 (184 mg, 48% yield based on Ho₂O₃), **3** (162 mg, 42% yield based on Er₂O₃) and **4** (204 mg, 52% yield based on Yb_2O_3) were prepared in a similar way as illustrated for 1. Anal. calcd (found) for $C_{12}H_{12}N_2O_{16}Dy_2$ (1): C 18.83 (19.21), N 3.66 (3.996), H 1.58 (1.59). IR spectra for **1** (KBr) *n*/cm-¹ : 3431 s, 2930 w, 1712 m, 1630 s, 1503 m, 1439 m, 1397 m, 1352 m, 1314 m, 1275 m, 1257 w, 1189 m, 1109 w, 982 w, 944 m, 875 m, 794 s, 697 m, 573 m, 501 m, 408 w. Anal. calcd (found) for C12H12N2O16Ho2 (**2**): C 18.72 (18.08), N 3.64 (3.44), H 1.57 (1.41). IR spectra for **2** (KBr) *n*/cm-¹ : 3444 s, 2926 w, 1714 m, 1633 s, 1504 m, 1441 m, 1398 m, 1353 m, 1315 m, 1275 m, 1190 m, 1108 w, 980 w, 960 m, 945 w, 875 w, 795 s, 697 m, 574 m, 501 m, 408 w. Anal. calcd (found) for $C_{12}H_{12}N_2O_{16}E_7$ (3): C 18.60 (19.26), N 3.62 (3.70), H 1.56 (1.55). IR spectra for **3**, (KBr) *n*/cm-¹ : 3444 s, 2926 w, 1716 w, 1632 s, 1504 m, 1440 m, 1398 m, 1353 m, 1315 m, 1274 m, 1190 w, 1110 w, 960 w, 876 w, 796 m, 696 w, 577 w, 501 w, 408 w. Anal. calcd (found) for C12H12N2O16Yb2 (**4**): C 18.33 (18.41), N 3.56 (3.61), H 1.54 (1.37). IR spectra for **4**, (KBr) *n*/cm-¹ : 3443 s, 2928 w, 1718 m, 1636 s, 1504 m, 1442 m, 1400 m, 1353 m, 1315 m, 1274 m, 1191 w, 1108 w, 960 w, 877 w, 797 m, 698 m, 575 m, 501 m, 408 m. § Crystal data for 1: triclinic, space group $P\bar{1}$ (#2), $a = 6.7426(16)$ Å, $b = 7.8105(18)$ Å, $c = 9.168(2)$ Å, $\alpha = 95.603(4)^{\circ}$, $\beta = 110.399(4)^{\circ}$, $\gamma = 93.470(4)°$, $V = 448.06(18)$ \AA^3 , $Z = 1$, $\rho_{\text{caled}} = 2.836$ g cm⁻³, $M_r = 555.34$ 765.24, μ (MoK α) = 8.370 mm⁻¹. Of the 3425 reflections collected, 1725 are independent ($R_{\text{int}} = 0.0177$) and 1705 are observed ($I > 2\sigma(I)$). On the basis of all the data and 145 refined parameters, R_1 (obs.) = 0.0217 and wR_2 (all data) = 0.0511 were obtained. For 2: triclinic, space group $P\overline{1}$ (#2), $a = 6.6964(15)$ Å, $b = 7.7827(18)$ Å, $c = 9.126(2)$ Å, $\alpha = 95.692(4)$ [°], $\beta =$ 110.274(3)[°], $γ = 93.543(4)$ [°], $V = 441.57(17)$ Å³, $Z = 1$, $ρ_{\text{cal}} = 2.896$ g cm⁻³, $M_r = 770.10, \mu(\text{MoK}\alpha) = 8.992 \text{ mm}^{-1}$. Of the 3329 reflections collected, 1680 are independent ($R_{\text{int}} = 0.0240$) and 1655 are observed ($I > 2\sigma(I)$). On the basis of all the data and 145 refined parameters, R_1 (obs.) = 0.0201 and wR_2 (all data) = 0.0560 were obtained. For 3: triclinic, space group $P\overline{1}$ (#2), $a = 6.6574(15)$ Å, $b = 7.7517(18)$ Å, $c = 9.066(2)$ Å, $\alpha = 95.676(4)$ [°], $\beta =$ $110.170(3)°$, $\gamma = 93.544(4)°$, $V = 434.73(17) \text{ Å}^3$, $Z = 1$, $\rho_{\text{cal}} = 2.959 \text{ g cm}^{-3}$, $M_r = 774.76$, μ (MoK α) = 9.685 mm⁻¹. Of the 3318 reflections collected, 1656 are independent ($R_{int} = 0.0182$) and 1640 are observed ($I > 2\sigma(I)$). On the basis of all the data and 145 refined parameters, R_1 (obs.) = 0.0186 and wR_2 (all data) = 0.0504 were obtained. For 4: triclinic, space group $P\overline{1}$ (#2), $a = 6.6649(15)$ Å, $b = 7.7808(17)$ Å, $c = 9.076(2)$ Å, $\alpha = 95.798(3)$ [°], $\beta =$ $109.928(3)°$, $\gamma = 93.594(3)°$, $V = 437.83(17)$ \AA ³, $Z = 1$, $\rho_{\text{caled}} = 2.982 \text{ g cm}^{-3}$, $M_r = 786.32$, μ (MoK α) = 10.713 mm⁻¹. Of the 3318 reflections collected, 1664 are independent ($R_{\text{int}} = 0.0219$) and 1659 are observed ($I > 2\sigma(I)$). On the basis of all the data and 145 refined parameters, R_1 (obs.) = 0.0206 and wR_2 (all data) = 0.0539 were obtained. Nobeling disting a strengther photon by Richard 1918¹ 4 S. Ho, LC. Chan, M. L. Tomas K. War man S. K. March 2011 Published by The Branch 2011 Published on 26 January 2012 11:30 (a strengther photon by The Published on 2

- 1 (*a*) W. Lin, O. R. Evans, R.-G. Xiong and Z. Wang, *J. Am. Chem. Soc.*, 1998, **120**, 13272; (*b*) O. R. Evans, Z. Wang, R.-G. Xiong, B. M. Foxman and W. Lin, *Inorg. Chem.*, 1999, **38**, 2969; (*c*) O. R. Evans and W. Lin, *Acc. Chem. Res.*, 2002, **35**, 511; (*d*) Q. Ye, Y.-H. Li, Y.-M. Song, X.-F. Huang, R.-G. Xiong and Z. Xue, *Inorg. Chem.*, 2005, **44**, 3618.
- 2 (*a*) X.-M. Chen and M.-L. Tong, *Acc. Chem. Res.*, 2007, **40**, 162; (*b*) X.-M. Zhang, *Coord Chem. Rev.*, 2005, **249**, 1201; (*c*) J.-P. Zhang, Y.-Y. Lin, X.-C. Huang and X.-M. Chen, *J. Am. Chem. Soc.*, 2005, **127**, 5495; (*d*) L. Cheng, W.-X. Zhang, B.-H. Ye, J.-B. Lin and X.-M. Chen, *Inorg. Chem.*, 2007, **46**, 1135; (*e*) J.-P. Zhang and X.-M. Chen, *Chem. Commun.*, 2006, 1689; (*f*) Y.-T. Wang, H.-H. Fan, H.-Z. Wang and X.-M. Chen, *Inorg. Chem.*, 2005, **44**, 4148; (*g*) X.-C. Huang, S.-L. Zheng, J.-P. Zhang and X.-M. Chen, *Eur. J. Inorg. Chem.*, 2004, 1024.
- 3 (*a*) J. Y. Lu, B. R. Cabrera, R.-J. Wang and J. Li, *Inorg. Chem.*, 1998, **37**, 4480; (*b*) J. Y. Lu, *Coord Chem. Rev.*, 2003, **246**, 327; (*c*) J. Y. Lu and A. M. Babb, *Inorg. Chem.*, 2002, **41**, 1339.
- 4 S. Hu, J.-C. Chen, M.-L. Tong, B. Wang, Y.-X. Yan and S. R. Batten, *Angew. Chem., Int. Ed.*, 2005, **44**, 5471; J. Tao, Y. Zhang, M.-L. Tong, X.-M. Chen, T. Yuen, C. L. Lin, X. Huang and J. Li, *Chem. Commun.*, 2002, 1342.
- 5 J.-K. Cheng, Y.-G. Yao, J. Zhang, Z.-J. Li, Z.-W. Cai, X.-Y. Zhang, Z.-N. Chen, Y.-B. Chen, Y. Kang, Y.-Y. Qin and Y.-H. Wen, *J. Am. Chem. Soc.*, 2004, **126**, 7796; O. R. Evans and W. Lin, *Cryst. Growth Des.*, 2001, **1**, 9.
- 6 A. J. Blake, N. R. Champness, S. S. M. Chung, W.-S. Li and M. Schröder, Chem. Commun., 1997, 1675; C.-M. Liu, S. Gao and H.-Z. Kou, *Chem. Commun.*, 2001, 1670; N. Zheng, X. Bu and P. Feng, *J. Am. Chem. Soc.*, 2002, **124**, 9688; Q.-H. Wei, L.-Y. Zhang, G.-Q. Yin, L.-X. Shi and Z.-N. Chen, *J. Am. Chem. Soc.*, 2004, **126**, 9940.
- 7 O. R. Evans, R.-G. Xiong, Z. Wang, G. K. Wong and W. Lin, *Angew. Chem., Int. Ed.*, 1999, **38**, 536; M.-L. Tong, L.-J. Li, K. Mochizuki, H.-C. Chang, X.-M. Chen, Y. Li and S. Kitagawa, *Chem. Commun.*, 2003, 428.
- 8 R.-G. Xiong, X. Xue, H. Zhao, X.-Z. You, B. F. Abrahams and Z. Xue, *Angew. Chem., Int. Ed.*, 2002, **41**, 3800; Z. P. Demko and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2002, **41**, 2110; Z. P. Demko and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2002, **41**, 2113; J.-P. Zhang, S.-L. Zheng, X.-C. Huang and X.-M. Chen, *Angew. Chem., Int. Ed.*, 2004, **43**, 206.
- 9 X.-X. Hu, J.-Q. Xu, P. Cheng, X.-Y. Chen, X.-B. Cui, J.-F. Song, G.-D. Yang and T.-G. Wang, *Inorg. Chem.*, 2004, **43**, 2261.
- 10 L. Han, X.-H. Bu, Q.-C. Zhang and P.-Y. Feng, *Inorg. Chem.*, 2006, **45**, 5736; J. Wang, S.-L. Zheng, S. Hu, Y.-H. Zhang and M.-L. Tong, *Inorg. Chem.*, 2007, **46**, 795.
- 11 D. A. Horton, G. T. Bourne and M. L. Smythe, *Mol. Diversity*, 2002, **5**, 289; V. Mas, A. Falco, I. Brocal, L. Perez, J. M. Coll and A. Estepa, *Antivir. Res.*, 2006, **72**, 107; N. Rameshkumar, M. Ashokkumar, E. H. Subramanian, R. Ilavarasan and S. K. Sridhar, *Eur. J. Med. Chem.*, 2003, **38**, 1001.
- 12 P. M. J. Fischer, *Peptide Sci.*, 2003, **9**, 9; A. Golebiowski, S. R. Klopfenstein, X. Shao, J. J. Chen, A.-O. Colson, A. L. Grieb and A. F. Russell, *Org. Lett.*, 2000, **2**, 2615; H.-O. Kim, H. Nakanishi, M. S. Lee and M. Kahn, *Org. Lett.*, 2000, **2**, 301; F. D'Angeli, P. Marchetti, R. Rondanin and V. Bertolasi, *J. Org. Chem.*, 1996, **61**, 1252; J. J. N. Veerman, R. S. Bon, B. T. B. Hue, D. Girones, F. P. J. T. Rutjes, Jan H. van Maarseveen and H. Hiemstra, *J. Org. Chem.*, 2003, **68**, 4486.
- 13 M. Tullberg, M. Grotli and K. Luthman, *J. Org. Chem.*, 2007, **72**, 195; A. L. Kennedy, A. M. Fryer and J. A. Josey, *Org. Lett.*, 2002, **4**, 1167; D. A. Parrish and L. J. Mathias, *J. Org. Chem.*, 2002, **67**, 1820; D.-X. Wang, M.-T. Liang, G.-J. Tian, H. Lin and H.-Q. Liu, *Tetrahedron Lett.*, 2002, **43**, 865; M. Falorni, G. Giacomelli, A. Porcheddu and M. Taddei, *Eur. J. Org. Chem.*, 2000, 1669.
- 14 A. R. TapiaBenavides, H. Tlahuext and R. Contreras, *Heterocycles.*, 1997, **45**, 1679.
- 15 M. R. Silva, A. M. Beja, J. A. Paixao, A. J. F. N. Sobral, L. M. L. Cabral and A. M. d. R. Gonsalves, *Acta Crystallogr., Sect. C: Cryst. Struct. Commun..*, 2003, **59**, o562.
- 16 C. Aronica, G. Pilet, G. Chastanet, W. Wernsdorfer, J.-F. Jacquot and D. Luneau, *Angew. Chem., Int. Ed.*, 2006, **45**, 4659.
- 17 *Cambridge Structural Database*, version 5.29 update, CCDC, Cambridge, U.K., Aug, 2008.
- 18 W. Ollendorf and F. Weigel, *Inorg. Nuclear Chem. Lett.*, 1969, **5**, 263; E. Hansson, *Acta Chem. Scand.*, 1973, **27**, 823.
- 19 (*a*) Y.-G. Huang, B.-L. Wu, D.-Q. Yuan, Y.-Q. Xu, F.-L. Jiang and M.-C. Hong, *Inorg. Chem.*, 2007, **46**, 1171; (*b*) Z.-H. Zhang, Y. Song, T.-A. Okamura, Y. Hasegawa, W.-Y. Sun and N. Ueyama,*Inorg. Chem.*, 2006, **45**, 2896; (*c*) G. Xu, Z.-M. Wang, Z. He, Z. Lu, C.-S. Liao and C.-H. Yan, *Inorg. Chem.*, 2002, **41**, 6802.
- 20 A. T. Casey and S. Mitra, in *Theory and Applications of Molecular Paramagnetism*, ed. E. A. Boudreaux and L. N. Mulay, J. Wiley and Sons, New York, 1976, p. 135.